Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses next steps in potential future research avenues following the results of her analysis into the risk of hematuria and proteinuria associated with rosuvastatin use.
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, discusses how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses the results of her research regarding the risks of hematuria and proteinuria with rosuvastatin use.
Galindo explained how the use of glucose-lowering agents in patients with diabetes and low eGFR improved patient care.
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how targeted therapies are impacting the treatment of NETs.
Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.
Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.
Galindo gave a general overview of his session and explained the new standards of care for chronic kidney disease which he has felt made a great impact on the field.
Mei Ka Fong, PharmD, BCOP, said sunitinib was the first targeted therapy for NETs, although other targeted agents are being investigated.
Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, addresses the questions surrounding the efficacy of perioperative octreotide treatment for patients experiencing a carcinoid crisis.
Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses how CBD and cannabinol can offer potential treatment options as more research is being brought to the forefront on these as integrative medicine.
Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses what octreotide is and how it is used to reduce carcinoid crisis rates or treat a crisis.
NETs can occur almost anywhere in the body, although they are most common in the gastrointestinal tract and lungs.
Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses his presentation at the 2021 NANETS Virtual Symposium on a prospective study of carcinoid crisis with no perioperative octreotide.
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how communication plays a huge role in treatment of neuroendocrine tumors in large cancer centers.
Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses why integrative treatment can help physicians personalize treatments for individuals with NETs and why it is beneficial to improve the quality of life for them.
Mei Ka Fong, PharmD, BCOP, said there are multiple treatment approaches for patients with NETs.
The CVS Health 2021 Health Care Insights Study found significant differences in how patients of various ages and genders approach care.
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses what kind of support services at large cancer centers can help individuals with neuroendocrine tumors with their treatment.
Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center, discusses how integrative medicine can help treatment of neuroendocrine tumors in combination with other treatments.
Pharmacists and technicians have an opportunity to prove their value as immunizers now that the Pfizer-BioNTech COVID-19 vaccine has been authorized for use in children ages 5 to 11.
Expert panelists delve into topics related to women's health and women's health care during the COVID-19 pandemic, including pregnancy and COVID-19 vaccine considerations and best practices for guiding decisions on birth control.
Board-certified oncology pharmacists Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, talk about exciting ongoing PARP inhibitor research concerning ovarian cancer.
Lindsay Bealor Greenleaf, MBA, JD, Vice President of ADVI Health, discusses a new poll from the Kaiser Family Foundation that found that 83% of Americans believe the government should be allowed to negotiate lower drug prices, for both those on Medicare and in private insurance plans.
Mark Garofoli, director of Experiential Learning Program at WVU School of Pharmacy, discusses his CPhT 2021 conference presentation regarding the role and impact of pharmacy technicians on opioids in the pharmacy.
Linda Mendonça, DNP, RN, PHNA-BC, president of the National Association of School Nurses, discusses a new poll released by the COVID-19 Vaccine Education and Equity Project and the National Association of School Nurses about parents’ plans to vaccinate their school-aged children.
Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, on his recent presentations at Insight 2021 and the virtual Sana Symposium on psychedelic adverse effects and drug-drug interactions.
Jamie L. McConaha, PharmD, NCTTP, BCACP, CDE, focuses on the safety and efficacy of systemic agents used to treat atopic dermatitis.
Emily Holcomb, PharmD, BCPS, ISMP Safe Medication Management Fellow, discusses her CPhT 2021 conference presentation regarding targeted medication safety best practices.
Nathan Bryson, PhD, chief scientific officer of Field Trip Health, said the company's new psychedelic compound, FT-104, could have potential uses in the treatment of postpartum depression.
